These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8272810)

  • 21. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [First infection with vancomycin resistant type VanA enterococci in a Norwegian hospital].
    Haarr E; Simonsen GS; Olsvik O; Sundsfjord A; Harbo K; Natås OB
    Tidsskr Nor Laegeforen; 1998 Mar; 118(8):1188-90. PubMed ID: 9567694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vancomycin resistant enterococci in Austria].
    Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Emergence of vancomycin-dependent enterococci following glycopeptide therapy: case report and review].
    Bert F; Leflon-Guibout V; Le Grand J; Bourdon N; Nicolas-Chanoine MH
    Pathol Biol (Paris); 2009 Feb; 57(1):56-60. PubMed ID: 18845404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
    Chien JW; Kucia ML; Salata RA
    Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gram-positive bacterial resistance: future treatment options.
    Bassetti M; Melica G; Di Biagio A; Rosso R; Gatti G; Bassetti D
    Curr Opin Investig Drugs; 2003 Aug; 4(8):944-52. PubMed ID: 14508878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vancomycin peak serum concentration monitoring.
    Tam VH; Moore GE; Triller DM; Briceland LL
    J Intraven Nurs; 1999; 22(6):336-42. PubMed ID: 10865602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Enterococcal resistance to glycopeptide antibiotics].
    Cercendado Mansilla E
    Rev Clin Esp; 1995 Oct; 195 Suppl 4():22-7. PubMed ID: 9441312
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of teicoplanin for Gram-positive infections in patients with kidney transplantation].
    Jákics J; Gálffy Z; Hernold L; Rácz A; Perner F
    Orv Hetil; 1996 Jun; 137(25):1355-8. PubMed ID: 8757082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teicoplanin: 10 years of clinical experience.
    Trautmann M; Wiedeck H; Ruhnke M; Oethinger M; Marre R
    Infection; 1994; 22(6):430-6. PubMed ID: 7698846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosynthesis, biotechnological production, and application of teicoplanin: current state and perspectives.
    Jung HM; Jeya M; Kim SY; Moon HJ; Kumar Singh R; Zhang YW; Lee JK
    Appl Microbiol Biotechnol; 2009 Sep; 84(3):417-28. PubMed ID: 19609520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control.
    Nelson RR
    J Hosp Infect; 1999 Aug; 42(4):275-82. PubMed ID: 10467540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
    Chow AW; Jewesson PJ; Kureishi A; Phillips GL
    Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vancomycin in 1991: current status and perspectives].
    Casetta A; Bingen E; Lambert-Zechovsky N
    Pathol Biol (Paris); 1991 Sep; 39(7):700-8. PubMed ID: 1758723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM; Bryson HM
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teicoplanin.
    Shea KW; Cunha BA
    Med Clin North Am; 1995 Jul; 79(4):833-44. PubMed ID: 7791426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.